[Fundamental studies on synthetic cephalosporin antibiotics. 2. Therapeutic effects of oral administration on experimental infections in mice and their distribution in the body].
D000667:Ampicillin / Q000627:therapeutic use; D000818:Animals; D002509:Cephaloridine / Q000032:analysis / Q000097:blood / Q000627:therapeutic use*; D002511:Cephalosporins / Q000378:metabolism; D002512:Cephalothin / Q000032:analysis / Q000097:blood / Q000627:therapeutic use*; D003023:Cloxacillin / Q000627:therapeutic use; D004009:Dicloxacillin / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000188:drug therapy*; D007668:Kidney / Q000032:analysis; D008099:Liver / Q000032:analysis; D008168:Lung / Q000032:analysis; D051379:Mice; D010068:Oxacillin / Q000627:therapeutic use; D010403:Penicillin Resistance; D010406:Penicillins; D011008:Pneumococcal Infections / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy*
D002511:Cephalosporins; D010406:Penicillins; D000667:Ampicillin; D004009:Dicloxacillin; D002509:Cephaloridine; D003023:Cloxacillin; D002512:Cephalothin; D010068:Oxacillin